Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT01318642 is registered in ClinicalTrials.gov with NantBioScience, Inc. as lead sponsor.

NCT NCT01318642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01318642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Lead sponsor
NantBioScience, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
December 3, 2012
Enrollment
10 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, locally advanced, unresectable